Skip to main content
. 2021 Apr 13;138(7):531–543. doi: 10.1182/blood.2020009515

Table 1.

Baseline characteristics of 38 patients who progressed and 18 patients without disease progression after CAR T-cell therapy

Characteristic Relapse after CAR T-cells, n = 38 No relapse after CAR T-cells, n = 18 P
Median age at CD19 CAR T-cell therapy (range), y 42.5 (23-74) 55 (23-68) .21
Male sex 28 (73.7%) 14 (77.8%) 1.00
Median lines of treatment before CAR T-cell therapy (range) 3 (2-7) 2 (1-7) .02
Philadelphia chromosome–positive ALL (%) p190 p210 13 (34.2) 8 (21.1) 5 (13.1) 4 (22.2) 3 (16.7) 1 (5.6) .74
Prior treatment with noncellular immunotherapy* (%) Blinatumomab Inotuzumab ozogamicin 10 (26.3) 3 (7.9) 3 (16.7) 1 (5.6) 1.00
Prior HSCT before CAR T-cell therapy (%) 17 (44.7) 3 (16.7) .11
Bridging therapy (%) Intensive therapy Nonintensive therapy None 10 (26.3) 21 (55.3) 7 (18.4) 10 (55.6) 7 (38.9) 1 (5.6) .12
Disease burden before CAR T-cell therapy (%) Morphologic disease MRD No evidence of disease 26 (68.4) 11 (28.9) 1 (2.6) 5 (27.8) 6 (33.3) 6 (33.3) .01
CRS post-CAR T-cell therapy (%) Grade 3 or higher CRS 32 (84.2) 9 (23.7) 16 (88.9) 6 (33.3) .52
ICANS (%) Grade 3 or higher ICANS 22 (57.9) 14 (36.8) 12 (66.7) 10 (55.6) .19
Tocilizumab for CRS/ICANS management (%) 15 (39.5) 5 (27.8) .39
Systemic corticosteroid for CRS/ICANS management (%) 12 (31.6) 7 (38.9) .59
Median time from CAR T-cell infusion to corticosteroid (range, d) 7 (5-15) 8 (3-12) .80
Median duration of systemic corticosteroid (range, d) 7 (1-15) 9 (2-27) .16
Median dose intensity of steroid (prednisone equivalent, mg/kg/d) 1.37 (0.72-2.58) 1.54 (0.79-6.75) .38
HSCT consolidation after CAR T-cell therapy (%) 6 (15.8) 9 (50.0) .10
*

One patient received both blinatumomab and inotuzumab ozogamicin before CD19 CAR T-cell therapy.

Intensive therapy included multiagent, myelosuppressive, chemotherapy-based regimen, and nonintensive regimen included nonmyelosuppressive chemotherapy or antibody-based therapy (eg, blinatumomab, inotuzumab). Breakdown of bridging intensity according to disease burden is provided in supplemental Figure 1.

Per American Society of Transplant and Cellular Therapy criteria.